SLDB Insider Trading Activity and SEC Form 4 Filings
SLDB insider trading summary
Over the past 12 months, insiders at Solid Biosciences Inc. (SLDB) reported 29 sales worth $2.7M by 7 insiders and no open-market purchases on SEC Form 4. Net insider selling was $2.7M.
Latest SLDB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 19, 2026 | Gabriel Brooks | Chief Medical Officer | Sell | $25K (4,374 @ $5.62) |
| Feb 18, 2026 | Jessie Hanrahan | Chief Regulatory Officer | Sell | $24K (4,134 @ $5.82) |
| Feb 18, 2026 | David T Howton | Chief Operating Officer | Sell | $43K (7,469 @ $5.82) |
| Feb 18, 2026 | Alexander Cumbo | President and CEO | Sell | $97K (16,644 @ $5.82) |
| Feb 18, 2026 | Gabriel Brooks | Chief Medical Officer | Sell | $0 (0 @ $5.82) |
| Feb 18, 2026 | Kevin Tan | CFO & Treasurer | Sell | $31K (5,404 @ $5.82) |
| Feb 18, 2026 | Ilan Ganot | Insider | Sell | $15K (2,658 @ $5.82) |
| Feb 18, 2026 | Paul Herzich | Chief Technology Officer | Sell | $21K (3,616 @ $5.82) |
| Feb 4, 2026 | David T Howton | Chief Operating Officer | Sell | $122K (18,894 @ $6.44) |
| Feb 4, 2026 | Kevin Tan | CFO & Treasurer | Sell | $95K (14,783 @ $6.44) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.